Related Experiment Video

Updated: Jun 15, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.4K

Multi-omics analysis delineates resistance mechanisms associated with BRAF inhibition in melanoma cells

Keshava K Datta1, Hitesh Kore2, Harsha Gowda3

  • 1Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Experimental Cell Research
|August 25, 2024
PubMed

Insights

Understanding BRAF inhibitor resistance in melanoma is key. This study used multi-omics in cell models to reveal resistance mechanisms and identify new therapeutic targets for melanoma treatment.

Area of Science:

  • Oncology
  • Genetics
  • Biochemistry

Background:

  • Mutant BRAF drives melanoma, making BRAF inhibitors (BRAFi) a key therapy.
  • Resistance to BRAFi, such as vemurafenib and dabrafenib, limits treatment effectiveness.
  • Understanding resistance mechanisms is crucial for developing more effective cancer drugs.

Purpose of the Study:

  • To characterize BRAF inhibitor resistance mechanisms in melanoma using in vitro models.
  • To identify novel therapeutic targets for overcoming BRAFi resistance.
  • To validate the utility of in vitro systems for predicting resistance and discovering drug targets.

Main Methods:

  • Utilized a multi-omics approach including exome sequencing, proteomics, and phosphoproteomics.
  • Developed and characterized BRAFi persister and resistant melanoma cell lines.
  • Analyzed genetic and non-genetic resistance mechanisms.

Main Results:

  • Identified common intrinsic and acquired genetic and non-genetic mechanisms of BRAFi resistance.
  • Revealed similarities between in vitro resistance mechanisms and those observed in patients.
  • Discovered potential protein targets for overcoming BRAFi resistance.

Conclusions:

  • In vitro cellular models are effective for studying and predicting BRAF inhibitor resistance in melanoma.
  • This research identified actionable therapeutic targets to overcome BRAFi resistance.
  • The findings pave the way for improved clinical outcomes in BRAF-mutant melanoma treatment.
Keywords:
Exome sequencingKinase inhibitorsPhosphoproteomicsProteomicsResistance

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

2.9K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.0K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K